400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
2020-09-29
FDA-2004-D-0124
指导原则
美国
现行有效
/
美国食品药品监督管理局(FDA)
GUIDANCE DOCUMENT
This guidance document identifies the device description, preclinical, clinical, and labeling information we recommend you present in a premarket approval application (PMA) for a breast implant. This guidance document may also be useful in preparing an application for an investigational device exemption (IDE). This document addresses breast implants filled with saline, silicone gel, or alternative filler intended for breast augmentation or breast reconstruction. This guidance document does not address tissue expanders, which are reviewed under the premarket notification (510(k)) process.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2004-D-0124.
摩熵医械2025-11-28
摩熵医械2025-11-17
赛柏蓝2025-11-14
摩熵医械2025-11-12
赛柏蓝2025-11-12
CHC医疗传媒2025-10-30
赛柏蓝2025-10-29
赛柏蓝2025-10-28
赛柏蓝2025-10-24
赛柏蓝2025-10-24
2025-12-01
2025-11-27
2025-11-26
2025-11-24
2025-11-24
2025-11-21
2025-11-18
2025-11-18
2025-11-17
2025-11-13
2025-11-13
2025-11-13
2025-11-11
2025-11-11
2025-11-11
2024-11-15
2024-11-14
2024-11-01
2024-10-31
2024-10-30
2024-10-24
2024-10-22
2024-10-21
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-16
2024-10-15
2025-11-17
2025-09-17
2025-09-17
2025-09-17
2025-07-21
2025-02-05
2025-01-31
2025-01-31
2025-01-07
2025-01-07
2025-01-07
2025-01-07
2025-01-07
2025-01-07
2025-01-07